Media.Player

Lipocalin-2 As A Prognostic And Diagnostic Marker For Heart And Stroke Risks

總結

Methods And Apparatus Are Disclosed For The Measurement Of Lipocalin-2 In Body Fluids (Including But Not Limited To Blood, Serum, Plasma, Urine, Saliva, Tear, Etc.) By An Assay Such As An Immunoassay Or An Immunotest For (1) The Prediction Of Risk Of Future Cardiovascular Diseases; And (2) The Determination Of The Likelihood That Certain Individuals Will Benefit To A Greater Or Lesser Extent From The Use Of Certain Treatments Designed To Prevent And/Or Treat Cardiovascular Diseases.

附加資料

Patent Number: CN102026655A
Application Number: CN200980116060A
Inventor: XU, Ai-min | AESCHLIMANN MARCEL | WANG, Yu | RENNEBERG REINHARD | CAUTHERLEY GEORGE WILLIAM HUNTER | CHEN, Pei-er
Priority Date: 30 Apr 2008
Priority Number: CN102026655A
Application Date: 16 Apr 2009
Publication Date: 20 Apr 2011
IPC Current: A61K003843 | A61P000900 | C07K001447 | G01N003353
Assignee Applicant: Versitech Ltd of HKU | Jevofar Co. Ltd.
Title: Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
Usefulness: Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
Summary: The methods are useful for characterizing a subject's risk or progression of cardiovascular disease; evaluating the likelihood that a subject will benefit from a treatment with an agent to reduce the risk of cardiovascular disease; reducing the risk of stroke, heart attack, or cardiovascular disease, or treating a cardiovascular disease; and treating or retarding the progression of a cardiovascular disorder in a mammalian subject. The lipocalin-2 is useful for manufacturing a medicament for characterizing a subject's risk or progression of cardiovascular disease, and for evaluating the likelihood that a subject will benefit from a treatment with an agent to reduce the risk of cardiovascular disease. The pharmaceutical agent capable of reducing lipocalin-2 concentrations in the body is useful for manufacturing a medicament for reducing the risk of stroke, heart attack, or cardiovascular disease or treating a cardiovascular disease. The pharmaceutical agent capable of reducing the level or effect of the subject's circulating lipocalin-2 in the body is useful for manufacturing a medicament for treating or retarding the progress of a cardiovascular disorder in a mammalian subject. The cardiovascular disease is chronic heart disease, acute coronary symptom, heart insufficiency, or stroke (all claimed).
Novelty: Characterizing a subject's risk or progression of cardiovascular disease by measuring the level of lipocalin-2 in the sample and comparing the subject's lipocalin-2 level to a predetermined reference value

主要類別

診斷/治療

細分類別

其他疾病

申請號碼

CN200980116060A

國家/地區

香港